What the FDA labels say about taking them together
Deferasirox and everolimus
Deferasirox's FDA label of January 28, 2026 names everolimus in its drug interactions section; the everolimus labels PlainMeds reads (2) do not name deferasirox. The deferasirox label: “Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4.”
Check it at the source: the deferasirox FDA label on DailyMed (effective January 28, 2026, Novartis Pharmaceuticals Corporation); the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation).
What does the deferasirox label say about everolimus?
Deferasirox label, drug interactionsClosely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) [see Clinical Pharmacology (12.3)].
Source: FDA drug label (Exjade), Novartis Pharmaceuticals Corporation, effective January 28, 2026 (SPL set 3495a70c-870c-4968-940e-8baea152cf85), via openFDA; the full label on DailyMed
What does the everolimus label say about deferasirox?
Everolimus's label (effective June 1, 2026) and its 1 other brand-application label do not name deferasirox in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Deferasirox | Everolimus | |
|---|---|---|
| Labeled for | n/a | Breast cancer, Seizures and epilepsy, Organ transplant rejection |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $1.25 per tablet 360 mg tablet | $26.32 per tablet 10 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once